Ruizhen Regenerative Medicine Technology
Advancing personalized regenerative medicine with iPSC technology
About Ruizhen Regenerative Medicine Technology
Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd., operating as Regen Therapeutics, is a biopharmaceutical firm established in January 2019 by a team of scientists in Guangzhou. The company focuses on the clinical translation of regenerative medicine, with a core emphasis on induced pluripotent stem cell (iPSC) technology. The legal representative, Chairman, and General Manager is Zhang Ling.
The company's operations are vertically integrated, encompassing research, production, and sales aimed at clinical stem cell therapy, drug development, and personalized precision medicine. Regen Therapeutics has established a comprehensive technology platform that covers the entire iPSC cell therapy process, including iPSC reprogramming and cell banking, differentiation techniques for immune and nerve cells, and gene modification for creating engineered iPS cell lines. This infrastructure is housed within a 2,500-square-meter GMP-grade cell production and R&D center, capable of meeting cell demands through Phase II clinical trials and storing thousands of standardized stem cell resources. A key milestone for the company was receiving the first patent authorization in China for its independently developed technology for differentiating dopamine precursor cells, which has shown promising therapeutic effects in primate models of Parkinson's disease.
Regen Therapeutics pursues a dual business model. It provides one-stop research services to pharmaceutical companies, medical institutions, and scientific research organizations, offering iPSC reprogramming and storage, iPSC-derived functional cells, and the production of exosomes and organoids. Concurrently, the company develops its own proprietary pipeline of universal, off-the-shelf cell therapy products derived from iPSCs for treating oncological and neurological disorders. Key pipelines include iDA-001 for Parkinson's disease, iNK001, a natural killer cell line for tumor immunotherapy, and an iMSN pipeline targeting the rare Huntington's disease. In May 2025, the company secured nearly CNY 100 million in a Pre-A financing round to advance these pipelines, particularly to support the IND application and investigator-initiated trials (IIT) for its Parkinson's treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 16.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Precision Medicine, Disease, Biotech and Pharma, Rare Diseases, DT and LS, science-based
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2025 | $14M | $55M | Canton Venture Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ruizhen Regenerative Medicine Technology in its local ecosystem
The Ruizhen Regenerative Medicine Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- CCCanton Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruizhen Regenerative Medicine Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruizhen Regenerative Medicine Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.




